Non-Small-Cell Lung Cancer: Practical Guidance for a Rapidly Evolving Treatment Paradigm

Review the latest data and expert guidance on managing patients with NSCLC. This comprehensive program features clinical commentaries a downloadable patient communication resource updates to the online interactive treatment decision support tools and a text-based module along with downloadable slides.

Share

Program Content

Activities

NSCLC Treatment Paradigm
Expert View on the Evolving Treatment Paradigm in Advanced NSCLC
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: June 23, 2020

Expires: June 22, 2021

Activities

Evolving Paradigm in NSCLC
Evolving Treatment Paradigm in Advanced Non-Small-Cell Lung Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 23, 2020

Expires: June 22, 2021

Activities

Frontline IO Combos
What’s New Regarding Frontline Immunotherapy Combinations in Advanced NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: December 30, 2019

Expires: December 28, 2020

IO for Squamous NSCLC
Using Immunotherapy to Treat Advanced Squamous NSCLC: Where Are We Now?
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 24, 2020

Expires: February 22, 2021

Biomarker Testing in Advanced NSCLC
My Approach to Biomarker Testing in Advanced NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 11, 2020

Expires: May 10, 2021

Dual IO for NSCLC
My Take on the Recent Approval of Dual Immune Checkpoint Inhibition for Advanced NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 06, 2020

Expires: July 05, 2021

Activities

NSCLC Communication Resource
Advanced NSCLC Management: A Resource for Talking With Your Patients
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: July 24, 2020

Expires: July 23, 2021

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Celgene

Loxo Oncology subsidiary of Eli Lilly

Partners

GRACE

ProCE Banner